Saturday, May 2, 2015

Google (GOOG) in Buyout Discussions With InterCloud Systems (ICLD) As Record $36M Order Backlog Reported Predicts Sierra World Equity Review

HEADLINE: Google (GOOG) in Buyout Discussions With InterCloud Systems (ICLD) As Record $36M Order Backlog Reported Predicts Sierra World Equity Review. Look for this deal to be done within 60 days in a straight cash transaction ventures Sierra.  Shares of ICLD finished higher up over 75% at the end of Friday's trading session. Look for the official news, when it breaks remember Sierra called this first!

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Past big winners include BSTO, XCLL, HHSE, UAPC, AEMD, XTRN, RGMI, PPCH, TSGL, GNPT, RCGP, IHSI, MLER and our last SCRH that doubled in a week!

Follow Sierra on Twitter To Get The Next PUBLISHER PICK~~Follow Sierra on Twitter

Our Latest Publisher Pick is Pacific Therapeutics (PCFTF) a small biotech company where INSIDERS in a private placement just participated in the purchase of $100 000 of shares and warrants. Wow what a BUY SIGNAL, with the current share price trading at historic lows under .02 cents the insiders are sending a clear message of their belief in the BRIGHT FUTURE for this company. The warrants may be exercised to purchase a common share for 0.15 cents for up to one year. That's over 700% higher than the current share price, what do the INSIDERS know?  Ask yourself this, who knows more about the company, you or the insiders, obviously the insiders do, NOW is the time for the average Joe to buy shares of PCFTF and follow the INSIDER BUYING!!
Insanely undervalued  trading at historic lows at under 2 cents a share Pacific Therapeutics (PCFTF) is making BIG waves with it's innovative pipeline drug PTL-202 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)There are no approved drugs for IPF and current treatments are ineffective!  Already with successful trials behind them and with continued success moving forward, it's easy to see now why insiders are loading, this stock will easily be trading in the multiple dollar range IF it is not acquired first by a big pharma, to illustrate this InterMune Inc. who’s lead product treats pulmonary fibrosis was recently sold to Roche Holdings for $8.3 billion proving the value of a therapy for fibrosis. Pacific Therapeutics (PCFTF) may have the cure not just a treatment!!! But it gets even BETTER they also have candidate PTL-2015 for the treatment of erectile dysfunction (ED) and revenues are anticipated to be massive!

With over 1.4 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest Publisher Pick Pacific Therapeutics (PCFTF).

Here's why our publisher has initiated a long position in Pacific Therapeutics (PCFTF):

Highlights:

Based in Vancouver BC Pacific Therapeutics (PCFTF)  is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. (Basically they take existing FDA approved drugs and make them better for use in treating other diseases!)

The Company’s lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

INSIDER BUYING:
April 1st 2015:  Pacific Therapeutics (PCFTF) announced on that insiders had in a private placement participated in the purchase of $100 000 of shares and warrants. The warrants may be exercised to purchase a common share for $0.15 for up to one year. (Wow what a BUY SIGNAL, with the current share price under .02 cents the insiders are sending a clear message of their belief in the BRIGHT FUTURE for this company. Ask yourself this, who knows more about the company, you or the insiders, obviously the insiders do, NOW is the time for the average Joe to buy shares of PCFTF and follow the INSIDER BUYING!!)

Share Structure:
Amazing share structure with only 37.4M O/S (this means that the share price can rise very quickly). Insiders own approximately 16% of the O/S and as indicated above are adding by purchasing more in private placements.

Pacific Therapeutics (PCFTF) intends to enter into partnering, co-promotion and other distribution arrangements to commercialize products in most markets

Pacific Therapeutics (PCFTF) will seek orphan status for certain indications that may be treated with its products specifically Idiopathic Pulmonary Fibrosis (IPF)

Pacific Therapeutics (PCFTF) has licensed patents and plans to license technologies and other patents and continues to develop a valuable portfolio of intellectual property rights to protect the technologies, inventions and improvements that includes patent applications in the United States, Europe and Canada.

Pacific Therapeutics (PCFTF) is a HIGH TARGET on the biotech buyout list, As successful trials continue, it's easy to see now why insiders are loading, this stock will easily be trading in the multiple dollar range if it is not acquired first by a big pharma, to illustrate this InterMune Inc. who’s lead product treats pulmonary fibrosis was recently sold to Roche Holdings for $8.3 billion proving the value of a therapy for fibrosis.

Pacific Therapeutics (PCFTF) with continued clinical trial and commercialization of it products will likely UPLIST to the NASDAQ sooner than later!

Business Strategy:
Pacific Therapeutics (PCFTF) mitigates the risks associated with development and commercialization of drug candidates by targeting drug candidates that: 
• are combinations of already approved compounds; 
• have well established safety records; 
• have potential to be reformulated to a once a day oral dose; 
• have potential to be reformulated to an oral dissolving technology; 
• are already marketed in countries other than the United States or Europe;
• have pre-clinical animal data or clinical data of potential efficacy in Fibrosis additional indications.

Lead drug Candidates:

PTL-202

PTL-202, the Company’s lead product candidate for fibrosis, has been tested in models of lung Fibrosis. These tests indicate that PTL-202 may be an effective drug to treat Pulmonary Fibrosis. (SO HUGE as currently there are no approved drugs to cure Idiopathic Pulmonary Fibrosis (IPF).
The Company’s lead product candidate for fibrosis (progressive scarring of the organ), PTL-202, is a combination of 2 drugs that have been separately approved for marketing by the FDA for sale in the United States.
The combination of drugs in PTL-202 is intended to stop the progression of IPF by reducing the amount of several messenger molecules that are known to be associated with scarring. In addition, the combination has anti-oxidant properties that protect the lung cells from further damage caused by the Fibrosis. In animal trials, the combination was more effective than either of its components at reducing indicators of Fibrosis.
A controlled release formulation of PTL-202, a fixed dose combination of PTX and NAC, for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF), Liver Cirrhosis and other fibrotic diseases was completed in 2012 with positive results. This study, conducted in humans in India, was intended to determine if any new by products are created by the combination of the drugs in PTL-202 and to determine if the combination is bioequivalent to its generic counter parts. Phase 1 was successful!
Phase 2 is next and will involve up to 65 patients with the company raising opting to raise $8M in private placement funding as opposed to utilizing toxic lenders. (Very good for the shareholders as once again it demonstrates that the insiders FIRMLY BELIEVE blue skies are ahead!)

Revenue potential for PTL-202:
Currently there are no approved drugs to cure Idiopathic Pulmonary Fibrosis (IPF).
Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK are forecast to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer. InterMune Inc. who’s lead product treats pulmonary fibrosis was recently sold to Roche Holdings for $8.3 billion proving the value of a therapy for fibrosis.

PTL-2015
The Company’s candidate for the treatment of erectile dysfunction (ED) is PTL-2015
As large pharmaceutical companies lose their patents on these drugs, a massive opportunity has developed for innovative formulations of drugs for ED. In November 2012 the Company executed a letter of intent with Globe Labs Inc. of Vancouver, BC for the potential in-license of an oral dissolving tablet technology. The technology may be used for the delivery of up to 3 different compounds. The initial use of the technology may be for the delivery of sildenafil citrate for the treatment of erectile dysfunction (“ED”). I
In 2011, the total market for drugs to treat ED exceeded $5 billion. The Company has finalized a license to an oral dissolving technology (“sublingual formulation”) of an approved drug to treat ED. Sales of the market leader alone exceeded $2 billion in 2012. The sublingual formulation improves on existing drugs for ED potentially acting faster and with fewer side effects. 
Revenue Potential for PTL- 2015
This is a very exciting development for the Company as it shortens the time to market for the Company’s first product and may add significantly to future revenuesWorking from the most conservative projections the British Journal of Urology expects the number of men with ED to more than double from 152 million in 1995 to 322 million by 2025. It is estimated that up to 20 million Europeans and 30 million North Americans experience recurring ED at some point in their lives (Life Science Intelligence). Total sales of ED drugs by the top 3 producers was $3.1 billion in 2006 growing rapidly to a total market of $5 billion in 2011. In addition, it is estimated that up to 90% of all ED goes undiagnosed, which is another driving force for market growth. Tablets using oral dissolve technology (ODT) are the most preferred and accepted solid dosing forms by patients. This dosage form is also considered by consumers to be of higher quality, having faster onset and being longer lasting than conventional tablets. In addition, 70% of consumers will ask their doctor for the ODT version of a drug if it is available. The Company plans to continue the development of PTL-2015 to gain marketing approval in the European Union
PTL-303
The Company’s other product candidate, PTL-303, is a combination of drugs including one that has been approved for use in Japan and other jurisdictions. This combination may have a wide range of uses, including treating, preventing and reducing disorders of progressive scarring in humans such as liver cirrhosis.
About Sierra World Equity Review
Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets and make speculative predictions on potential joint ventures, mergers and acquisitions.

Sierra World Equity Review and it's publisher have not been compensated to promote Pacific Therapeutics (PCFTF) but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.